Results 241 to 250 of about 121,016 (287)

From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies. [PDF]

Front Immunol
Feng Y, Yang Z, Zhou Y, Liang Y, Zhao H.
europepmc   +1 more source

Recent Advances in Bioconjugation of Aromatic Amino Acid Residues by a Reactivity‐Guided Approach

The Chemical Record, EarlyView.
This review highlights recent advances in the bioconjugation of aromatic amino acids residues, focusing on strategies that leverage their inherent chemical reactivity to enable precise and versatile modifications of biomacromolecules, illustrating relevant applications.
Bruno M. da S. Santos, Lívia C. R. M. da Frota, Thais G. Silva, Fernanda G. Finelli   +3 more
wiley   +1 more source

Immune Effector Cell-Associated Neurotoxicity Delayed Relapse After Chimeric Antigen Receptor T-Cell Therapy: A Case Report. [PDF]

Neurol Neuroimmunol Neuroinflamm
Favero A, Mohamed S, Battista ML, Cenacchi V, Sartori A, Mazzon G, Bratina A, Tomaselli M, Patriarca F, Zaja F, Manganotti P, Benussi A.   +11 more
europepmc   +1 more source

Microfluidic single‐cell technologies for immunotherapeutic target discovery: From design concepts to preclinical applications

VIEW, EarlyView.
Immunotherapy leverages the immune system to treat cancer and autoimmune diseases but is hindered by cellular heterogeneity in tissues and immune landscapes. Single‐cell technologies, particularly microfluidic‐enabled omics, revolutionize disease understanding by resolving this complexity at unprecedented resolution.
Haopu Wang, Kangfu Chen, Zongjie Wang
wiley   +1 more source

CAR-NK Engineering to Overcome TME Barriers. [PDF]

Cells
Islam F, Pupovac A, Boyd RL, Trounson AO.   +3 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Age‐ and Sex‐Adjusted Body Mass Index Increases in Childhood Acute Lymphoblastic Leukaemia Patients From Diagnosis to Five‐Year Follow‐Up

Acta Paediatrica, EarlyView.
ABSTRACT Aim Children with acute lymphoblastic leukaemia (ALL) are at risk of metabolic and cardiovascular complications. We evaluated the development of overweight and obesity for 5 years after diagnosis in children and adolescents treated for ALL. Methods The medical records of children diagnosed with ALL at one centre during 2000–2018 were assessed.
Aino Kytömäki, Anu Huurre, Päivi M. Lähteenmäki, Tero Vahlberg, Liisa S. Järvelä   +4 more
wiley   +1 more source

CAR-T in the Treatment of Solid Tumors-A Review of Current Research and Future Perspectives. [PDF]

Int J Mol Sci
Picheta N, Piekarz J, Daniłowska K, Szklener K, Mańdziuk S.   +4 more
europepmc   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy for stiff-person syndrome: bridging innovation and clinical challenges in neuroimmunology. [PDF]

Ther Adv Neurol Disord
Wickel J, Motte J, Ayzenberg I, Vlad B, Gold R, Geis C, Faissner S.   +6 more
europepmc   +1 more source